Trametinib dimethyl sulfoxide is under clinical development by Novartis and currently in Phase II for Lung Adenocarcinoma. According to GlobalData, Phase II drugs for Lung Adenocarcinoma does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Trametinib dimethyl sulfoxide LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Trametinib dimethyl sulfoxide overview

Trametinib (GSK1120212, Mekinist) is an anti-cancer agent. It is formulated as tablets, film coated tablets, coated tablets, powder for solution for oral route of administration. Trametinib is indicated as a single agent or in combination with dabrafenib for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by a FDA-approved test. The use in combination is based on the demonstration of durable response rate. Improvement in disease-related symptoms or overall survival has not been demonstrated for Mekinist in combination with dabrafenib. Mekinist in combination with dabrafenib, for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by a FDA-approved test.

Trametinib is under development for the treatment of cholangiocarcinoma, metastatic biliary tract carcinoma, differentiated thyroid cancer (DTC), gallbladder cancer, lung adenocarcinoma, cetuximab-refractory colorectal cancer in combination with panitumumab, metastatic pancreatic cancer, plexiform neurofibroma, Langerhans cell histocytosis, arterio-venous malformations, anaplastic thyroid cancer, ampulla of Vater cancer). refractory and relapsed Multiple Myeloma, triple-negative breast cancer, endometrial cancer in combination with uprosertibm. It is under development for low grade glioma. It is also underdevelopment for the treatment of solid tumors, which may include but are not limited to rhabdomyosarcoma and other soft tissue sarcomas, Ewing sarcoma family of tumors, osteosarcoma, neuroblastoma, Wilms' tumor, hepatic tumors, germ cell tumors, primary brain tumors, NF-1 associated PF and LCH.

It was under development for the treatment of lymphoma and metastatic uveal melanoma, relapsed or refractory leukemia including acute myeloblastic leukemia, myelodysplastic syndrome,  advanced or metastatic biliary tract cancer (cholangiocarcinoma, gallbladder cancer, chronic myelomonocytic leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia ,glioma and metastatic transitional (urothelial) tract cancer and Trametinib in combination with dabrafenib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation, and it was also under development for the treatment of colorectal cancer, bladder cancer, pancreatic cancer, non-small cell lung cancer, ovarian cancer, head and neck cancer squamous cell carcinoma in combination with uprosertib. Afuresertib in combination with trametinib was under development for the treatment of prostate cancer, renal cell carcinoma, gastric cancer and hepatocellular cancer.

Novartis overview

Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, hematologic diseases, solid tumors, immune disorders, and infections, among others. Novartis conducts research in various disease areas through the BioMedical Research division. The company operates through a network of subsidiaries and offices across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.

For a complete picture of Trametinib dimethyl sulfoxide’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.